
Opinion|Videos|November 9, 2023
KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer
Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
2
Adagrasib Plus Cetuximab Falls Short in KRAS G12C–Mutated Colorectal Cancer
3
The Growing Rationale for Earlier Targeting of GPRC5D in Multiple Myeloma
4
FDA OKs ProstACT Trial Part 2 Protocol for Metastatic Prostate Cancer
5











































